Global
EN CN
Discovery and development of First-in-class/Best-in-class small molecule innovative drug
Novel discovery platforms of targeted protein degradation (TPD), with a commitment on areas of autoimmunity and oncology, leveraging new unmet medical needs and the synergistic combinations to transform patients life.
LeadingTac’s first protein degrader has commenced a Phase I clinical study in China in June 2024
Leadingtac is dedicated to the discovery and development of nano-SPUD® innovative drug to advance the precision protein degrader system
Leadingtac management team has most members from both Chinese, American and European biotech and pharmaceutical companies. Excelling their perspectives and expertise in the field of small molecule drug development, specifically the in the field of protein degradation
We will always share with you a little bit of what we do
2024-08-08
Big congratulations to Dr. Zhengqing Ye of Leadingtac was awarded with one of the “Pearl Elite Talent” in Pudong New Area in 2024
2024-08-08
Big congratulations to Dr. Yan Shuang of Leadingtac was awarded with one of the “Pearl Elite Talent” in Pudong New Area in 2024
2024-06-26
Leadingtac Announces First Healthy Volunteer Dosed in a Phase 1 Clinical Program of LT-002, a Potentially best-in-class IRAK4 degrader
2024-02-28
LeadingTac: Leading the Targeted Protein Degradation Track to Make Global Innovative Innovative Drugs
2023-12-15
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi
2023-12-12
Big congratulations to Dr. Yan Feng of Leaddingtac was awarded with one of the first few of "Pearl Leading Talent" in Pudong New Area
2023-10-31
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi
2023-10-25
Leadingtac Announces CDE Approval of Phase I Clinical Trial for LT-002 for the treatment of Hidradenitis Suppurativa
2023-09-25
Kymera and its partner Sanofi announced plans to initiate a Phase 2 clinical trial of IRAK4 degrader KT474/SAR444656 in HS in the fourth quarter of 2023
2023-09-13
Leadingtac received the award "Shanghai 2023 technology innovation funds for small and medium-sized enterprises" project
2024-08-08
Big congratulations to Dr. Zhengqing Ye of Leadingtac was awarded with one of the “Pearl Elite Talent” in Pudong New Area in 2024
2024-08-08
Big congratulations to Dr. Yan Shuang of Leadingtac was awarded with one of the “Pearl Elite Talent” in Pudong New Area in 2024
2024-06-26
Leadingtac Announces First Healthy Volunteer Dosed in a Phase 1 Clinical Program of LT-002, a Potentially best-in-class IRAK4 degrader
2024-02-28
LeadingTac: Leading the Targeted Protein Degradation Track to Make Global Innovative Innovative Drugs
2023-12-15
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi
2023-12-12
Big congratulations to Dr. Yan Feng of Leaddingtac was awarded with one of the first few of "Pearl Leading Talent" in Pudong New Area
2023-10-31
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi
2023-10-25
Leadingtac Announces CDE Approval of Phase I Clinical Trial for LT-002 for the treatment of Hidradenitis Suppurativa
2023-09-25
Kymera and its partner Sanofi announced plans to initiate a Phase 2 clinical trial of IRAK4 degrader KT474/SAR444656 in HS in the fourth quarter of 2023
2023-09-13
Leadingtac received the award "Shanghai 2023 technology innovation funds for small and medium-sized enterprises" project
Company Mailbox
Incoming Email
Official Account